USA flag logo/image

An Official Website of the United States Government

Live-Cells Assays for Lysosomal Enzyme Activity

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85871
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
MH079542
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MARKER GENE TECHNOLOGIES, INC
1850 MILLRACE DRIVE 1850 MILLRACE DRIVE EUGENE, OR 97403 1992
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2007
Title: Live-Cells Assays for Lysosomal Enzyme Activity
Agency: HHS
Contract: 1R43MH079542-01
Award Amount: $399,644.00
 

Abstract:

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to develop new targeted fluorogenic substrates capable of measuring lysosomal enzyme activity in living cells and tissues. If successful, the proposed researc h will provide breakthroughs needed to advance the discovery of promising new therapies and modulating drugs for lysosomal storage diseases and allied medical applications. In Phase I of this project, Marker Gene Technologies, Inc. will establish the feasi bility of the technology by preparing new fluorogenic glycosidase substrates for lysosomal enzymes and demonstrating differential staining in living cells that are from normal or are of disease origin. In Phase II, these new substrates will be assayed in v itro and in vivo for their ability to measure specific and localized inhibition or induction of lysosomal enzymes in living cells as well as differentiate individual enzyme activities in a cell- or tissue-specific manner. The new substrates and the resulti ng detection systems will provide innovative methods to quantitate lysosomal enzyme function and to screen for the influence of secondary drug or protein administration, making them useful analytical tools for a variety of significant medical applications. The success of this project opens up enormous commercial possibilities in the fields of medical intervention in lysosomal storage diseases such as Sandhoff's disease, Tay-Sachs syndrome, Krabb 's disease and Gaucher's disease, as well as in the screening of new proteins and drugs in cell-culture systems for efficacy in modulating lysosomal enzyme activity in these diseases, and development of new, general and specific high-throughput lysosomal enzyme detection strategies. In addition, it will lead to comme rcial and licensable products in these areas.

Principal Investigator:

John J. Naleway
5413423760
JNALEWAY@UOREGON.EDU

Business Contact:

Angela A. Naleway
analeway@markergene.com
Small Business Information at Submission:

MARKER GENE TECHNOLOGIES
MARKER GENE TECHNOLOGIES, INC. University of Oregon Riverfront Research Park EUGENE, OR 97403

EIN/Tax ID: 931228900
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No